1. Introduction
During the past decade the development of medical therapies for the treatment of the inflammatory arthopathies such as rheumatoid arthritis (RA) was revolutionized by the development of disease modifying anti-rheumatic biological drugs (DMARBDs) (Ŝenolt et al., 2009). DMARBDs were first discovered to be effective by altering intracellular signaling pathways and those gene expressional events that have proven to be relevant to RA pathogenesis and progression through the use of experimental studies in pre-clinical
2. Animal models of RA
Animal models of human RA have proven to be critical for determining the potential efficacy of DMARBDs for subsequent use in the treatment of human RA. The DMARBDs that are now employed for RA therapy were always first tested in RA animal models where the molecular events governing the onset and progression of RA disease activity could be rigorously and longitudinally assessed (Wooley, 2008; Leung et al., 2010). The DMARBDs that targeted pro-inflammatory cytokines relevant to RA progression such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), IL-6, IL-12/IL-23 and IL-17 as well as other molecules whose activity correlated with progressive RA disease activity, such as CTLA-4 and CD20/CD-22 were shown to significantly modify the progression of inflammatory arthritis in mice (Finckh & Gabay, 2008).
3. The use of DMARBDs in RA
Despite improvement in the frequency of positive clinical responses in RA patients that have been obtained using DMARBDs when combined with immunosuppressive drugs such as methotrexate, the chronic use of DMARBDs in RA therapy has also revealed that serious adverse events typified by the onset of new infections, the development of refractoriness to DMARBDs as well as the long term specter of potential malignancies have also been documented (Salliot et al., 2009). These long-term treatment considerations have resulted in the need for a continuous stream of development of additional and hopefully novel RA therapies that specifically target molecules intimately involved in RA progression. One strategy that has been utilized for this purpose is the development of gene therapy for RA (Gaddy & Robbins, 2008; Jorgensen & Apparailly, 2010; Traister & Hirsh, 2008; Woods et al., 2008)
4. Gene therapy for RA
Over the past 7 years or so a considerable amount of research activity has been devoted to the development of gene therapeutic strategies that have resulted in 1) neutralization of the effects of IL-1 with an IL-1 receptor antagonist (IL-1-Ra) expression plasmid (Kim et al.; 2003); 2) elevating the levels of Th2 cytokines exemplified by IL-10 (Traister & Hirsh, 2008), IL-4 (Kageyama et al., 2004) and IL-13 (Nabbe et al., 2005); 3) suppression of Th1 cytokines such as IL-18 (Smeets et al., 2003) and IL-17, the latter by modification of the indoleamine 2,3-dioxygenase pathway (Chen et al., 2011); 4) blunting of TNF-α-stimulated signaling (Denys et al., 2010) and interferon-β activity (Adriaansen et al.; 2006); 5) up-regulation of the protein inhibitor of activated STAT1 (PIAS) activity by stimulating the capacity of small ubiquitin-like modifier E3 ligase (SUMO E3) to alter inhibitor of κB kinaseα (IKKα) phosphorylation (Liu & Shuai, 2008); 6) gene transfer of genetically modified chondrocytes into cartilage defects to promote cartilage regeneration (Steinert et al., 2008); and 7) promotion of adiponectin gene expression (Ebina et al., 2009). In addition, because new blood vessel formation is also intimately involved with perpetuating the chronic state of inflammation associated with RA, experimental gene therapy strategies designed to suppress the activity of pro-angiogenesis factors such as vascular endothelial growth factor (VEGF) (Afuwape et al., 2003) and Tie-2 (Chen et al., 2005) have also been earnestly pursued.
There also exists an elevated frequency of apoptotic cells in RA articular cartilage joints which is likely to contribute to diminished chondrocyte vitality (Malemud & Gillespie, 2005). By contrast, resistance to induction of apoptosis in RA synovial-like fibroblasts (Hutcheson & Perlman, 2008) and up-regulation of chemokines and adhesion molecules (Malemud & Reddy, 2008) are generally considered to be hallmarks of synovial tissue hyperplasia. Thus, apoptosis, chemokines and adhesion molecules may also be suitable targets for gene therapy strategies.
4.1. Novel gene therapy strategies and improvements in the delivery of gene constructs
Several gene therapy strategies have taken advantage of recent advances in silencing RNA (siRNA) technology (Aigner, 2008; Blagbrough & Zara, 2009; Li & Huang, 2008; Lu & Woodle, 2008). Thus, siRNA has already been employed to generate tolerogenic dendritic antigen-presenting cells (Khan et al., 2009; Zheng et al., 2010) or to “shut-down” pro-inflammatory cytokine production (Khoury et al., 2008). siRNAs have also been incorporated into a gene “cream” for delivery to inflamed synovial joints. This concept has already been used to regulate the biological activity of molecules such as osteopontin in a rodent model of RA (Takanashi et al., 2009).
Most importantly, vast improvements have occurred in developing new strategies for administering gene constructs. This has been achieved through the use of non-viral vectors (Adriaansen et al., 2006) adeno-associated viral (AAV) vectors (Tang et al., 2010) or lentiviral vectors (Gouze et al. 2002). In that regard, the development of useful vectors for preparing gene constructs has taken on greater significance in the field. Thus, these various approaches to delivering gene constructs of interest to synovial joints are likely to be critical because the improved administration of gene constructs and/or plasmids will be instrumental for future studies designed to regulate the activities of such RA-related molecules such as IL-17, IL-18, CD40/nuclear factor-κB, COT/Tpl-2 and extracellular matrix degrading proteinases to name just a few relevant targets for ameliorating inflammatory arthritis
The major emphasis in this chapter has been placed on systematically analyzing the recent advances since 2007-2008 when this field was last reviewed (Malemud, 2007; Woods et al., 2008; Dai et al., 2008). Thus, this review will focus its attention on several novel modalities for developing gene constructs as well as emerging strategies for delivering genes to inflamed synovial joints in the murine or rat Type II collagen-induced arthritis (CIA) model of RA (Wooley, 2008). This animal model of inflammatory arthritis is considered useful for the pre-clinical assessment of safety, tolerability and efficacy of gene constructs for their potential application to human RA.
5. Gene therapy in the CIA model
5.1. Pro-inflammatory and anti-inflammatory cytokines
The imbalance between pro-inflammatory cytokines such as IL-1, TNF-α and IL-6 and anti-inflammatory cytokines such as IL-4 and IL-10 have been shown to be a significant driving force in the progression of inflammation in animal models of arthritis and as such the gene targeting of these cytokines would be expected to alter the progress of arthritis severity (van de Loo & van den Berg, 2002). Thus, polarization of T-helper type 1 cells (Th1) to T-helper type 2 cells (Th2) in favor of Th1 appears to be at the root cause of immune-mediated dysfunction in RA (Asquith & McInnes, 2007). In RA, Th1/ Th2 polarization appears to account, at least in part, for the skewed repertoire of pro-inflammatory cytokines to anti-inflammatory cytokines. This change appears to be coupled to the deficient production and/or activity of Th2 cytokines, exemplified by IL-4 and IL-10, which may also account for accelerating the progression of RA. Additionally, the genesis of a specific T-cell subset, termed Th17, also activates a key intracellular signaling pathway in RA, namely, JAK/STAT (Malemud, 2010). It has been postulated that activation of JAK/STAT signaling causes acute synovitis to progress into a chronic destructive arthritis (Khoury et al., 2008; Lubberts, 2008). It was not unexpected that gene therapy strategies employed in CIA have been directed at neutralizing the activity of IL-1, and/or TNF-α or towards augmenting the production of the anti-inflammatory cytokines, IL-4 and/or IL-10. Several of these studies have yielded some promising results.
There have been significant advances in suppressing the activity of TNF-α in several animal models of arthritis through targeted gene therapy. Thus, Adriaansen et al. (2007) showed that a recombinant AAV5 vector (rAAV5) encoding the NF-κB-TNFR1-Ig construct reduced paw swelling in the rat arthritis model which was accompanied not only by decreased levels of TNF-α, but also by reduced levels of IL-1β and IL-6 whereas the level of IL-10 was increased. These results suggested that a coupling mechanism between TNF-α and IL-1/IL-6 must be pertinent to arthritis progression in CIA if suppression of TNF-α gene expression resulted in lower levels of IL-1β/IL-6 and elevated levels of IL-10 as well. Importantly, the rAAV5 vector remained localized to the injected joint and no trace of rAAV5 was found in the periphery. The suppressive effect of a rAAV5 vector encoding TR1 fused to the Fc portion of mouse IgG1 (i.e. TNFRp55 extracellular domain-Ig) on inflammation was also seen in murine CIA (Khoury et al., 2007). In that study, there was a robust correlation between decreased levels of local TR1 and markers of inflammation that contributed to an overall reduction in the inflammation score.
Gould et al. (2007) employed a novel gene delivery system using plasmid vectors pGTLMIK and pGTTMIK from which luciferase and a dimeric TNF receptor were co-expressed in a doxycycline-regulated fashion, to show that administered GTTMIK delayed the onset of arthritis in murine CIA and the progression of inflammation as measured by reduced paw thickness. Additionally, the clinical score diminished but only when doxycycline was co-administered. The results of this study indicated that suppression of murine CIA could be achieved by inhibiting TNF-α-mediated events via gene expression-specific regulation. Inoue et al. (2009) used siRNAs which are double-stranded oligonucleotides that are designed to perfectly pair with the targeted mRNA in order to cause mRNA degradation to show that intra-articular delivery of TNF-α or IL1β-specific siRNAs reduced inflammation in rat CIA. The results of this study also showed that siRNA duplexes when administered
Finally, Lai Kwan Lam et al. (2008) employed siRNA technology using a lentivirus-regulated B-cell activating factor (Lv-shBAFF) to limit BAFF levels. BAFF is a critical molecule in RA because it promotes the survival of activated B-cells (Townsend et al., 2010). In this study, Lv-shBAFF suppressed BAFF production. However, and unexpectedly so, silencing of BAFF gene expression also reduced the activity of Th17 cells as well as B-cell activity in murine CIA. The suppression of Th17 cell-mediated activity was accompanied by reduced synovial tissue inflammation. Moreover, Lv-shBAFF reduced the percentage of mice developing CIA by around 50% and reduced the onset time for arthritic pathology. Of note, computer tomography scanning failed to detect any narrowing of the joint space or changes in bone erosions when mice with CIA who had had Lv-shBAFF administered were compared to mice with CIA who were injected with an LV vector expressing shRNA for β-actin. In accompanying
5.2. Signal transduction pathways
Gene targeting of the JAK/STAT and PI3K/Akt/PTEN/mTOR signal transduction pathways have been considered as an alternative to orally-administered enzyme inhibitors to suppress immune-mediated inflammation in animal models of arthritis (Camps et al., 2005; Milici et al., 2008) as well as for inflammatory disorders in general (Ghigo et al., 2010). In that regard, Hildner et al. (2007) showed that targeting STAT4 by antisense phosphorothioate oligonucleotides reduced inflammation in murine CIA. In a correlative analysis (Hildner et al., 2007), STAT-4 deficient mice also developed significantly less severe arthritis than their wild-type counterparts. Further, T-cells recovered from the STAT-4 deficient mice produced less IL-6, TNF-α and IL-17. In another interesting study, adenoviral vectors encoding PTEN (AdPTEN) or β-galactosidase (AdLacZ) were injected directly into the joints of rats with CIA (Wang et al., 2008). AdPTEN was shown to reduce ankle circumference, articular cartilage degradation, radiographic and histology scores compared to rats with CIA injected with AdLacZ. AdPTEN also reduced microvessel density as well as VEGF and IL-1β levels while suppressing Akt activation. The suppressed activity of Akt correlated with a concomitant increase in the frequency of apoptotic cells in the arthritic ankle joints of rats with CIA. Taken together these results indicated that down-regulation of the PI3K/Akt/PTEN/mTor pathway by AdPTEN gene transfer could be an effective future strategy for not only suppressing the neoangiogenic response in synovial tissue that is a hallmark of joints with inflammatory arthritis (Szekanecz & Koch, 2008) but also as an alternative to using small molecule enzyme inhibitors in order to increase apoptosis in arthritic apoptosis-resistant synovial tissue (Hutcheson & Perlman, 2008).
5.3. T-cells, growth factors, metalloproteinase(s) and assorted other gene targets
T-cell receptor (TCR) gene transfer was originally proposed as a novel approach for use in antigen-specific immunotherapy (Fujio et al., 2006). Thus, in lupus-prone NZB/W F1 mice, nucleosome-specific TCRs and CTLA4-Ig-transduced cells suppressed autoantibody production and the development of nephritis whereas in CIA, TCRs recovered from T-cells that accumulated in the affected arthritic joints combined with TNFR-Ig -transduced cells or TCRs in combination with Forkhead box p3 (Foxp3) transcription factor-transduced cells, the latter a marker of the regulatory T-cell phenotype (Haque et al., 2010) suppressed the progression of arthritis and reduced bone erosions (Fujio et al., 2007a, 2007b). These results indicated that the production of antigen-specific T-cells engineered to express specific functional genes could be a productive immunotherapeutic strategy for future considerations in the treatment of human autoimmunity and arthritis.
Several growth factors pertinent to the abnormal increase in microvascular density that is a characteristic of RA synovial tissue have been targeted by gene constructs, including, VEGF (Afuwape et al., 2003), Ang-1 and Tie-2 (Fielder & Augustin, 2006). Because increased levels of synovial tissue Tie-2 and Ang-1 were shown to correlate with aberrant neoangiogenesis in CIA (DeBusk et al. 2003), Chen et al. (2005) studied the extent to which arthritis in CIA could be regulated by a Tie-2 gene construct. Thus, the severity of arthritis was markedly reduced when an adenovirus vector containing a soluble Tie-2 receptor (Ad.ExTek) was locally administered after the onset of arthritis. In addition, Ad.ExTek protected mice with CIA against bony erosions, suppressed neoangiogenesis, reduced the level of RANKL, but did not suppress anti-Type II collagen antibody production. However, a search of the PubMed literature since 2007 did not reveal any current studies directed at targeting angiogenesis via either Ang-1 or Tie-2 gene therapy suggesting that a greater focus has been placed on defining a common thread such as PI3K/Akt/PTEN/mTor pathway activation as a way of regulating neoangiogenesis in CIA (Wang et al., 2008).
The failure of chondrocytes to respond to insulin-like growth factor-1 (IGF-1) has been proposed as one of the mechanisms that underlie the inefficient repair of articular cartilage in arthritis (van de Loo et al., 2008). Although the results of a study (Nixon et al., 2005) showed that synovial membrane co-transduced
Three additional targets for which gene therapy has been employed in experimental models of arthritis are worthy of comment. The down-regulation of MMP gene expression and inhibition of MMP activation are critical mechanisms for regulating cartilage and bone extracellular matrix degradation in RA (Zafarullah et al., 2008). Chia et al. (2008) employed the mouse model of CIA to show that the MMP-9 (92kDa gelatinase) gene was up-regulated in both the acute and chronic (late) stage of mouse CIA whereas elevated IL-1β gene expression was limited only to the acute stage of CIA. This result suggested that targeting MMP-9 by gene therapy could significantly limit the destruction of cartilage and bone extracellular matrix in CIA. Furthermore, because the activity of MMP-9 is regulated by neutrophil gelatinase-associated lipocalin (NGAL) which prevents the autocatalytic degradation of pro-MMP-9 (Gupta et al., 2007), NGAL synthesis could also be targeted by gene therapy to determine the extent to which down-regulating NGAL gene expression reduces the onset and/or severity of arthritis in CIA. Resistance to induction of apoptosis in RA synoviocytes results in perpetuating the inflammatory response in RA synovium for which several intracellular pathways that regulate the induction of apoptosis are known to converge contributing to RA pathogenesis and progression, including the development of pannus (Baier et al., 2003; Ospelt et al., 2004; Sweeney & Firestein, 2004; Malemud & Gillespie, 2005). Since it would be unlikely that inhibiting only one of these intracellular signaling pathways would induce apoptosis in RA synovium (Malemud, 2011), it was notable that Chen et al. (2009) showed that an E1B-55-kDa-deleted AV (Ad.GS1) driven by the human telomerase reverse transcriptase promoter induced cytolysis of human RA synovial fibroblasts and synoviocytes from rats with CIA
6. Conclusions
Significant progress has been made in the potential for future medical therapies of RA to employ gene therapy. In that regard, a few gene therapy strategies have already been tested in cell cultures and pre-clinical animal models of arthritis most notability in the CIA model in mice and rats. Of note, several targets for gene therapy such as IL-1Ra, TNF-α, and IL-17 have already yielded DMARBDs or other forms of neutralizing compounds which are either currently being assessed in pre-clinical studies, tested in RA clinical trials or routinely used in the treatment of RA in clinical practice (Genovese et al., 2010; Finckh & Gabay, 2008; Gibbons & Hyrich, 2009; Ishiguro et al., 2011; Sênolt et al., 2009; Toh et al., 2010). However, the positive results obtained with various gene therapy strategies in cell cultures and/or in animal models of arthritis must always be cautiously interpreted as the previous supportive results with inhibitors of p38 kinase in arthritis animal models (Böhm et al., 2009; Hammaker & Firestein, 2010) which provided the impetus for the clinical testing of p38 kinase inhibitors proved to be disappointing in terms of clinical outcomes in human RA trials (Genovese, 2009). Thus, it remains to be seen if the biopharmaceutical industry will use pertinent targets for RA intervention such as IL-10, BAFF, MMP-9, etc. in gene therapy studies so that the effects of these gene constructs can be pre-clinically assessed. In addition, an increased attention to the potential negative biological effects of the viral vectors so commonly used to regulate the activity of these gene constructs must also take place. If no toxic or adverse effects occur in pre-clinical testing, then and only then should these gene constructs be further developed for their eventual assessment in RA.
Acknowledgments
Research in the Malemud laboratory is funded by Takeda Pharmaceuticals of North America and by Roche/Genentech. No further conflicts of interest relevant to this article were reported.
References
- 1.
Adriaansen J. Vervoordeldonk M. J. Vanderbyl S. et al. 2006 A novel approach for gene therapy: engraftment of fibroblasts containing the artificial chromosome expression system at the site of inflammation. 8(1):63 71 - 2.
Adriaansen J. Khoury M. de Cortie C. J. et al. 2007 Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. 66(9):1143 1150 - 3.
Afuwape A. O. Feldmann M. Paleolog E. M. 2003 Adenoviral delivery of soluble VEGF receptor (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Therapy 10(23):1950 1960 - 4.
(Aigner A. 2008 ) Cellular delivery in vivo of siRNA-based therapeutics.14 (34 ): pp.3603 -3619 . - 5.
Asquith D. L. Mc Innes I. B. 2007 Emerging cytokine targets in rheumatoid arthritis. 19(3):246 251 - 6.
Baier A. Meineckel I. Gay S. Pap T. 2003 Apoptosis in rheumatoid arthritis. 15(3):274 279 - 7.
Blagbrough I. S. Zara C. 2009 Animal models for target diseases in gene therapy-using DNA and siRNA delivery strategies. 26(1):1 18 - 8.
Böhm C. Hayer S. Kilian A. et al. 2009 The α isoform of p38 kinase MAPK specifically regulates arthritic bone loss. 183(9):5938 5947 - 9.
Camps M. Rückle T. Ji H. et al. 2005 Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. 11(9):936 943 - 10.
Chia W. T. Chen Y. W. Cheng L. Y. et al. 2008 MMP-9 mRNA as a therapeutic marker in acute and chronic stages of arthritis induced by type II collagen antibody. 107(3):245 252 - 11.
Chen S. Y. Shiau A. L. Shieh G. S. et al. 2009 Amelioration of experimental arthritis by a telomerase-dependent conditionally replicating adenovirus that targets synovial fibroblasts. 60(11):3290 3302 - 12.
Chen S. Y. Wu C. L. Lai M. D. et al. 2011 Amelioration of rat collagen-induced arthritis through CD4+ T cells apoptosis and synovial interleukin-17 reduction by indoleamine 2, 3-dioxygenase gene therapy. 22(2):145 154 - 13.
Chen Y. Donnelly E. Kobayashi H. et al. 2005 Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. 52(5):1585 1594 - 14.
Choi Y. Arron J. R. Townsend M. J. 2009 Promising bone-related therapeutic targets for rheumatoid arthritis. 5(10):543 548 - 15.
Cylwik B. Chrostek L. Gindzienska-Sieskiewicz E. et al. 2010 Relationship between serum acute-phase proteins and high disease activity in patients with rheumatoid arthritis. 55(1):80 85 - 16.
Dai K. R. Zhang X. L. Shi Q. Fernandes J. C. 2008 Gene therapy of arthritis and orthopaedic disorders: current experimental approaches in China and in Canada. 8(9):1337 1346 - 17.
De Busk L. M. Chen Y. Nishishita J. et al. 2003 Tie2 receptor kinase, a major mediator of tumor necrosis factor-α-induced angiogenesis in rheumatoid arthritis. 48(9):2461 2471 - 18.
Denys A. Thiolat A. Descamps D. et al. 2010 Intra-articular electrotransfer of mouse soluble tumour necrosis factor receptor in a murine model of rheumatoid arthritis. 12(8):659 668 - 19.
Ebina K. Oshima K. Matsuda M. et al. 2009 Adenovirus-mediated gene transfer of adiponectin reduces the severity of collagen-induced arthritis in mice. 378(2):186 191 - 20.
Feely M. G. Erickson A. O’Dell J. R. 2009 Therapeutic options for rheumatoid arthritis. 10(13):2095 2106 - 21.
Fielder U. Augustin H. G. 2006 Angiopoietins: a link between angiogenesis and inflammation. 27(12):552 558 - 22.
Finckh A. Gabay C. 2008 At the horizon of innovative therapy in rheumatology: new biological agents. 20(3):269 275 - 23.
Fujio K. Okamoto A. Araki Y. et al. 2006 Gene therapy of arthritis with TCR isolated from the inflamed paw. 177(11):8140 8147 - 24.
Fujio K. Okamura T. Okamoto A. Yamamoto K. 2007a T cell receptor gene therapy for autoimmune diseases. 1110:222 232 - 25.
Fujio K. Okamura T. Okamoto A. Yamamoto K. 2007b T-cell receptor- and anti-inflammatory gene-modulated T cells as therapy for autoimmune disease. 3(6):883 890 - 26.
Gaddy D. F. Robbins P. D. 2008 Current status of gene therapy for rheumatoid arthritis. 10(5):398 404 - 27.
Genovese M. C. 2009 Inhibition of p38: has the fat lady sung? 60(2):317 320 - 28.
Genovese M. C. van den Bosch. F. Robertson S. A. et al. 2010 LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis; a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. 62(4):929 939 - 29.
Ghigo A. Damilano F. Braccini L. Hirsch E. 2010 PI3K inhibition in inflammation: toward tailored therapies for specific diseases. 32(3):185 196 - 30.
Gibbons L. J. Hyrich K. L. 2009 Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. 23(2):111 124 - 31.
Gould D. Yousaf N. Fatah R. Subang M. C. Chernajovsky Y. 2007 Gene therapy with an improved doxycycline-regulated plasmid encoding a tumour necrosis factor-alpha inhibitor in experimental arthritis. 9(1): Pg.R7 EOF - 32.
Gouze E. Pawliuk R. Pilapil C. et al. 2002 In vivo gene delivery to synovium by lentiviral vectors. 5(4):397 404 - 33.
Grimstein C. Choi Y. K. Satoh M. et al. 2010 Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis. 12(1):35 44 - 34.
Grimstein C. Choi Y. K. Wasserfall C. H. 2011 Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model. 9:21 - 35.
Gupta K. Shukla M. Cowland J. B. et al. 2007 Neutrophil gelatinase-associated lipocalin (NGAL) is expressed in osteoarthritis and forms a complex with matrix metalloproteinase-9. 56(10):3326 3335 - 36.
Hammaker D. Firestein G. S. 2010 Go upstream, young man”: lessons learned from the p38 saga. 69 Suppl 1:i77 i82 - 37.
Haque R. Lei F. Xiong X. Wu Y. Song J. 2010 FoxP3 and Bcl-xL cooperatively promote regulatory T cell persistence and prevention of arthritis development. 12(2): Pg.R66 EOF - 38.
Hildner K. M. Schirmacher P. Atreya I. et al. 2007 Targeting of the transcription factor STAT4 by antisense phosphorothioate oligonucleotides suppresses collagen-induced arthritis. 178(6):3427 3436 - 39.
Hutcheson J. C. Perlman H. 2008 Apoptotic regulators in RA. 4(4):254 258 - 40.
Inoue A. Takahashi K. A. Mazda O. et al. 2009 Comparison of anti-rheumatic effects of local RNAi-based therapy in collagen-induced arthritis rats using various cytokine genes as molecular targets. 19(2):125 133 - 41.
Ishiguro A. Akiyama T. Adachi H. Inoue J. Nakamura Y. 2011 Therapeutic potential of anti-interleukin-17 aptamer. Suppression of interleukin-17A signaling and attenuation of autoimmunity in two mouse models. 63(2):455 466 - 42.
Izal I. Acosta C. A. Ripalda P. et al. 2008 IGF-1 gene therapy to protect articular cartilage in a rat model of joint damage. 128(2):239 247 - 43.
Jorgensen C. Apparailly F. 2010 Prospects for gene therapy in inflammatory arthritis. 24(4):541 552 - 44.
Kageyama Y. Koide Y. Uchijima M. et al. 2004 Plasmid encoding interleukin-4 in the amelioration of murine collagen-induced arthritis. 50(3):968 975 - 45.
Khan S. Greenberg J. D. Bhardwaj N. 2009 Dendritic cells as targets for therapy in rheumatoid arthritis. 5(10):566 571 - 46.
Kim J. M. Jeong J. G. Ho S. H. et al. 2003 Protection against collagen-indued arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist. 10(8):1543 1550 - 47.
Kivirikko K. I. Myllyla R. Pihlajaniemi T. 1989 Protein hydroxylation: prolyl 4-hydroxylase, an enzyme with 4 cosubstrates and a multifunctional subunit. 3(5):1609 1617 - 48.
Khoury M. Adriaansen J. Vervoordeldonk M. J. et al. 2007 Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis. 9(7):596 604 - 49.
Khoury M. Courties G. Fabre S. et al. 2010 Adeno-associated virus type 5-mediated intraarticular administration of tumor necrosis factor small interfering RNA improves collagen-induced arthritis. 62(3):765 770 - 50.
Khoury M. Escriou V. Courties G. et al. 2008 Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. 58(8):2356 2367 - 51.
Lai Kwan. Lam Q. King Hung. Koo O. Zheng B. J. Lu L. 2008 Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. 105(39):14993 14998 - 52.
Leung P. S. Shu S. A. Kenny T. P. Wu P. Y. Tao M. H. 2010 Development and validation of gene therapies in autoimmune diseases: Epidemiology to animal models. 9(5):A400 A405 - 53.
Li S. D. Huang L. 2008 Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. 9(12):1317 1323 - 54.
Liu B. Shuai K. 2008 Targeting the PIAS1 SUMO ligase pathway to control inflammation. 29(10):505 509 - 55.
Lu P. Woodle M. C. 2008 Delivering small interfering RNA for novel therapeutics. 437:93 107 - 56.
Lubberts E. 2008 IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? 41(2):84 91 - 57.
Malemud C. J. 2007 Gene therapy for arthritis. 11:27 36 - 58.
Malemud C. J. 2010 Differential activation of JAK enzymes in rheumatoid arthritis and autoimmune disorders by pro-inflammatory cytokines: potential drug targets. 2:97 111 - 59.
Malemud C. J. 2011 Dysfunctional immune-mediated inflammation in rheumatoid arthritis dictates that development of anti-rheumatic disease drugs target multiple intracellular signaling pathways. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (In Press) - 60.
Malemud C. J. Gillespie H. J. 2005 The role of apoptosis in arthritis. 1(1):131 142 - 61.
Malemud C. J. Miller A. H. 2008 Pro-inflammatory cytokine-induced SAPK/MAPK and JAK/STAT in rheumatoid arthritis and the new anti-depression drugs. 12(2):171 183 - 62.
Malemud C. J. Pearlman E. 2009 Targeting JAK/STAT signaling pathway in inflammatory diseases. 4:201 221 - 63.
Malemud C. J. Reddy S. K. 2008 Targeting cytokines, chemokines and adhesion molecules in rheumatoid arthritis. 4(4):219 234 - 64.
Marone R. Cmiljanovic V. Giese B. Wymann M. P. 2008 Targeting phosphoinositide-3-kinase: moving towards therapy. 1784(1):159 185 - 65.
Milici A. J. Kudlacz E. M. Audoly L. Zwillich S. Changelian P. 2008 Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. 10(1): Pg.R14 EOF - 66.
Nabbe K. C. van Lent P. L. Holthuysen A. E. et al. 2005 Local IL-13 gene transfer prior to immune-cartilage complex arthritis inhibits chondrocyte death and matrix-metalloproteinase-mediated cartilage matrix degradation despite enhanced joint inflammation. 7(2):R392 R401 - 67.
Nixon A. J. Haupt J. L. Frisbie D. D. et al. 2005 Gene-mediated restoration of cartilage matrix by combination insulin-like growth factor/interleukin-1 receptor antagonist therapy. 12(2):177 186 - 68.
Ospelt C. Neidhart M. Gay R. E. Gay S. 2004 Synovial activation in rheumatoid arthritis. 9:2323 2334 - 69.
Salliot C. Dougados M. Gossec L. 2009 Risk of serious infections during rituximab, abatacept and anakinra treatment for rheumatoid arthritis: meta-analysis of randomised placebo-controlled trials. 68(1):25 32 - 70.
Ŝenolt L. Vencovský J. Pavelka K. Ospelt C. Gay S. 2009 Prospective new biological therapies for rheumatoid arthritis. 9(2):102 107 - 71.
Szekanecz Z. Koch A. E. 2008 Targeting angiogenesis in RA. 4(4):298 303 - 72.
Smeets R. L. van de Loo F. A. Arntz O. J. et al. 2003 Adenoviral delivery of IL-18-binding protein C ameliorates collagen-induced arthritis in mice. 10(12):1004 1011 - 73.
Steinert A. F. Nöth U. Tuan R. S. 2008 Concepts of gene therapy for cartilage repair. 39 Suppl 1:S97 S113 - 74.
Sweeney S. E. Firestein G. S. 2004 Rheumatoid arthritis: regulation of synovial inflammation. 36(3):372 378 - 75.
Takanashi M. Oikawa K. Sudo K. et al. 2009 Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse. 16(8):982 989 - 76.
Tang B. Cullins D. L. Zhou J. et al. 2010 Modulation of collagen-induced arthritis by adenovirus-mediated intra-articular expression of modified collagen type II. 12(4): pg.R136 EOF - 77.
Toh M. L. Kawashima M. Hot A. Miossec P. Miossec P. 2010 Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12Rβ2 inhibition. 69(8):1562 1567 - 78.
Townsend M. J. Monroe J. G. Chan A. C. 2010 B-cell targeted therapies in human autoimmune diseases: an updated perspective. 237(1):264 283 - 79.
Traister R. S. Hirsch R. 2008 Gene therapy for arthritis. 18(1):2 14 - 80.
van de Loo F. A. Veenbergen S. van den Berg. W. B. 2008 Targeting growth factors in arthritis: a rational for restoring the IGF-1 response in chondrocytes. 4(4):266 277 - 81.
van de Loo F. A. van den Berg. W. B. 2002 Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators. 28(1):127 149 - 82.
Walker J. G. Ahern M. J. Coleman M. et al. 2006 Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. 65(2):149 156 - 83.
Wang C. R. Shiau A. L. Chen S. Y. et al. 2008 Amelioration of collagen-induced arthritis in rats by adenovirus-mediated PTEN gene transfer. 58(6):1650 1656 - 84.
Wisler B. A. Dennis J. E. Malemud C. J. 2011 New organ-specific pharmacological strategies interfering with signaling pathways in inflammatory disorders/autoimmune disorders. - Supplement: Towards tailoring treatment- New organ-specific drug strategies interfering in signal pathway (in press) - 85.
Woods J. M. Sitabkhan Y. Koch A. E. 2008 Gene therapy for rheumatoid arthritis: recent advances. 8(1):24 41 - 86.
Wooley P. H. 2008 Which animal models are best for testing novel RA therapies? 4(4):277 287 - 87.
Zafarullah M. Ahmad R. El Mabrouk M. et al. 2008 Inhibition of matrix metalloproteinases a a feasible therapeutic target in RA. 4(4):288 297 - 88.
Zheng X. Suzuki M. Ichim T. E. et al. 2010 Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. 184(11):6457 6464